WCE 2017: Prostate Cancer Screening: How to use PSA in 2017
Out of 351 patients retrospectively identified between 2008 and 2016 with baseline eGFR ≥ 60, both kidneys, a T1a tumor, and a R.E.N.A.L. score < 10, 82 patients who underwent MAC and 41 patients who underwent OC were screened and analyzed. Perioperative factors including margins, complications, blood loss, and operative time were compared between these two cohorts of patients. There were no statistically significant differences in baseline demographic or tumor-specific characteristics such as tumor size or R.E.N.A.L. scores when patients were matched.
It was determined that there was a greater estimated blood loss (EBL) for OC patients than MAC patients. Besides this singular factor, there was no significant difference in any of the following categories: complications, excisional volume loss, acute kidney injury, percent change in eGFR at discharge, progression to chronic kidney disease, and percent change in eGFR at last follow-up.
Dr. Blum concluded his presentation by reaffirming that OC treatment is safe. However, he did want to educate the audience in his conclusion that there is an increased risk of a greater perioperative EBL and there is no functional outcome benefit in patients with a T1a renal tumor without compromised renal function.
Authors: Daniel C. Rosen, Kyle A. Blum, David J. Paulucci, Ronney Abaza, Daniel D. Eun, Akshay Bhandari, Ashok K. Hemal, Ketan K. Badani
Affiliation: Icahn School of Medicine – Mount Sinai
Speaker: Kyle Blum, MD
Written By: Zachary Valley, Department of Urology, University of California-Irvine at the 35th World Congress of Endourology – September 12-16, 2017, Vancouver, Canada